Last $0.52 USD
Change Today 0.00 / 0.00%
Volume 0.0
ONCS On Other Exchanges
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $0.97
52 Week Low
10/1/13 - $0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a drug-medical device and therapeutic company, designs, develops, and commercializes medical approaches for the treatment of solid tumors in the United States. The company is developing technology based on the proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Its clinical programs include three Phase II clinical trials to assess the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions, Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

12 Employees
Last Reported Date: 12/10/13

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $390.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $247.2K
Compensation as of Fiscal Year 2013.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Announces Executive Changes

OncoSec Medical Incorporated has appointed Mai H. Le, M.D. to the position of Chief Medical Officer. In this role, Dr. Le will oversee worldwide clinical development and regulatory activities for OncoSec's intratumoral cancer immunotherapy programs. In addition, Robert Pierce, M.D., who previously served as Chief Medical Officer, has been named to the newly created position of Chief Scientific Officer and Global Head of R&D. Furthermore, Tu Diep, M.Sc., who has served as Executive Director, Clinical Development, will now assume the position of Vice President of Operations. Prior to joining OncoSec, Dr. Le was medical director at Calithera Biosciences Inc., where she formulated and launched the early clinical development plans for a novel small molecule inhibitor of glutaminase for a variety of solid and hematological tumor indications.

OncoSec Medical Incorporated Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 01:30 PM

OncoSec Medical Incorporated Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 01:30 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

OncoSec Medical Appoints Holbrook Kohrt to Scientific Advisory Board

OncoSec Medical Inc. has appointed Dr. Holbrook Kohrt to the company's Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline. Holbrook E. Kohrt is an Assistant Professor at Stanford Cancer Institute, and currently investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. During this time he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.52 USD 0.00

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at